Piper Jaffray analyst Charles Duncan maintains overweight rating and $40 price target on Aimmune Therapeutics Inc. (NASDAQ: AIMT), as the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE